Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-086674
Filing Date
2025-09-11
Accepted
2025-09-11 08:14:42
Documents
3
Period of Report
2025-09-11

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0256928-6k_enlivex.htm 6-K 9379
2 LETTER ISSUED BY ENLIVEX THERAPEUTICS LTD. ON SEPTEMBER 11, 2025 ea025692801ex99-1_enlivex.htm EX-99.1 27110
3 GRAPHIC ex99-1_001.jpg GRAPHIC 19776
  Complete submission text file 0001213900-25-086674.txt   65210
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV Israel
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV Israel 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 251307261
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)